Neoadjuvant Systemic Therapy for Prostate Cancer: If a PUNCH Is Good, What Will It Take to Score a Knockout?
With all the randomized trial data supporting a survival benefit of androgen deprivation therapy with primary radiation to the prostate, it is unfortunate that the same results have not been achieved in combination with radical prostatectomy. The data has been replicated in multiple randomized controlled trials, confirming that addition of androgen deprivation therapy in a neoadjuvant, concurrent and adjuvant fashion to definitive primary local radiation leads to a survival benefit for men with high-risk prostate cancer.1
Evan Yu, MD
Evan Yu, a medical oncologist, treats prostate, bladder, and testicular cancer, and is passionate about providing a personalized medical approach to a selection of novel therapies as well as understanding biologic mechanism of drug sensitivity and resistance.
Medical Oncology, Translational Research, Novel molecular targeted agents, Biomarkers, Imaging (PET scans, MRI), Bone health.
- Professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine
- Member, Clinical Research Division, Fred Hutchinson Cancer Research Center
- Clinical Research Director, Genitourinary Oncology, Seattle Cancer Care Alliance
- Medical Director, Clinical Research Service, Fred Hutchinson Cancer Research Consortium
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember: Talk to your health care providers first before making decisions about your health care. Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.